Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Treatment response
Study Overview
Brief Summary
The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Outcomes Assessor)
Eligibility Criteria
- Ages
- 6 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosis of alopecia areata
- •SALT score of less than 50% extension
- •Has not received any topical or systemic treatment in the last month
- •Signed informed consent
Exclusion Criteria
- •Any skin condition on the scalp (infectious, inflammatory or neoplastic) that could modify the clinical of trichoscopic features
- •Pregnancy or breast-feeding
- •Patients in medications that could cause hair loss as side-effects
Arms & Interventions
intralesional Triamcinolone
Triamcinolone acetonide will be administered intralesionally at a concentration of 4 mg/mL. The solution will be injected in 0.1 mL doses, spaced 1 cm apart. The maximum total dose per session will be limited to 3 mL
Intervention: Candida Albicans Antigen Injection (Drug)
Candida albicans antigen
Single subcutaneous administration of 0.1 mL of Candida albicans antigen into one of the alopecic patches
Intervention: Candida Albicans Antigen Injection (Drug)
Outcomes
Primary Outcomes
Treatment response
Time Frame: 5 months
porcentage of hair growth determined by SALT score
Secondary Outcomes
- Side effects(5 months)
Investigators
Erika Lizbeth Alba Rojas
Erika Alba Rojas
Universidad Autonoma de Nuevo Leon